




# CENTRAL NERVOUS SYSTEM



SUBJECT : Pharmacology

LEC NO. : 1

DONE BY : Batool ALzubaidi

وَقُلْ رَبِّ زِدْنِي عِلْمًا




# Introduction

Pharmacology and Toxicology  
Central Nervous System Module  
Third Year Medical Students  
Tareq Saleh, MD, PhD  
Faculty of Medicine  
The Hashemite University

# The Neuron

For communication and signaling


Functional unit of central nervous system, all drugs that work on cns will affect the neuron somehow






All neurons work by exhibiting an action potential but it differs whether it's inhibitory or excitatory, and from which circuit it's working



# Action Potential



# Action Potential



ال action potential ما بصير بال neuron مرة وحدة بحدث على شكل segments و ينتقل على طول ال axon لحد ما يوصل ال terminal



MakeAGIF.com



The resting membrane potential is established by the electrochemical gradient of      $K^+$     

Depolarization occurs mainly due to the influx of      $Na^+$     

Hyperpolarization occurs mainly due to the efflux of      $K^+$     


The type of ion channel that accounts for rapid depolarization is  
    **Voltage-gated  $Na^+$  Channels**    

Action potentials move in one direction. T or F?

In the central nervous system the post synaptic structure is a neuron

# The Synapse

When action potential reaches the terminal of the neuron it will result with it's activation » the neuron will and up releasing the neurotransmitter .. There's different types of neurons depending on neurotransmitter they release which depends on the function but all of them undergo prestorage of neurotransmitters inside presynaptic vesicles so they're ready to be released as soon at the action potential reaches the terminal



action potential will also cause voltage gated calcium channels to open resulting in entry of calcium ions which play an important role in degranulating the neurotransmitter containing vesicles to the synaptic cleft where they bind to their receptors on postsynaptic neuron membrane, and it's the main site of degradation of neurotransmitters some neurotransmitters get reuptaken and degraded within the presynaptic neuron





# Neurotransmitters

Action / effect of activation of presynaptic neuron differs from neuron to another » that what treats the diversity of membrane functions

Must be endogenous » must be synthesized by neurons

If substance is neuro active but not synthesized within the neuron » not a neurotransmitter

- Endogenous chemicals that enable neurotransmission
- Released by the arrival of action potential (depolarization) at the nerve ending

↳ Not at a random time



# What Makes a Chemical Substance a Neurotransmitter?

- 1) The chemical must be synthesized in the neuron.
- 2) When the neuron is active, the chemical must be released and produce a response in some target.
- 3) The same response must be obtained when the chemical is experimentally placed on the target. → Consistency of the response
- 4) A mechanism must exist for removing the chemical from its site of activation after its work is done. ↓

Neurotransmitters must have pathways to synthesize it as well as to remove it ( degradation and metabolism ) to terminate their effect

# Types of CNS neurotransmitters

- **Acetylcholine**

Excitatory

- Nicotinic and muscarinic receptors

- **Amino acids**

Inhibitory neurotransmitter in the brain and spinal cord

- ❖ **GABA** (gamma-aminobutyric acid)

- GABA<sub>A</sub> and GABA<sub>B</sub> receptors

- ❖ **Glycine**

Most dominant inhibitory

- Glycine receptors

- ❖ **Glutamate**

Most dominant excitatory

- AMPA and NMDA receptors

Different receptors » different functions but it's excitatory in both cases

- **Biogenic Amines**

- ❖ **Catecholamines**

- Norepinephrine**

- Adrenergic receptors

- Dopamine:**

- Dopamine receptors

- ❖ **Serotonin**

- Serotonin receptors

- **Peptides**

- ❖ **Endogenous opioids**

- Opioids receptors

- ❖ **Substance P**



# Excitatory Neurotransmitters

- Acetylcholine

❖ Glutamate



# Inhibitory Neurotransmitters

❖ **GABA** (gamma-aminobutyric acid)

❖ **Glycine**

❖ **Endogenous opioids**



# Excitatory vs Inhibitory

- **Acetylcholine**

- **Amino acids**

- ❖ **GABA**

- ❖ **Glycine**

- ❖ **Glutamate**

- **Biogenic Amines**

- ❖ **Catecholamines**

- Norepinephrine**

- Dopamine**

- ❖ **Serotonin**

They exert mixed function they could be excitatory or inhibitory depending on the pathway and the receptor

- **Peptides**

- ❖ **Endogenous opioids**




NEUROTRANSMITTER		POSTSYNAPTIC EFFECTS
BIOGENIC AMINES	Acetylcholine	<b>Excitatory:</b> Involved in arousal, short-term memory, learning and movement.
	Norepinephrine	<b>Excitatory:</b> Involved in arousal, wakefulness, mood, and cardiovascular regulation.
	Dopamine	<b>Excitatory:</b> Involved in emotion, reward systems and motor control.
	Serotonin	<b>Excitatory/inhibitory:</b> Feeding behavior, control of body temperature, modulation of sensory pathways including nociception (stimulation of pain nerve sensors), regulation of mood and emotion, and sleep/wakefulness.
AMINO ACIDS	GABA	<b>Inhibitory:</b> Increases $Cl^-$ flux into the postsynaptic neuron, resulting in hyperpolarization. Mediates the majority of inhibitory postsynaptic potentials.
	Glycine	<b>Inhibitory:</b> Increases $Cl^-$ flux into the postsynaptic neuron, resulting in hyperpolarization.
	Glutamate	<b>Excitatory:</b> Mediates excitatory $Na^+$ influx into the postsynaptic neuron.
NEURO-PEPTIDES	Substance P	<b>Excitatory:</b> Mediates nociception (pain) within the spinal cord.
	Met-enkephalin	<b>Generally inhibitory:</b> Mediates analgesia as well as other central nervous system effects.

# ① Excitatory Postsynaptic Potentials (EPSP)

- Release of an excitatory NT
- NT binds to its receptor on the postsynaptic neuron
- Influx of  $\text{Na}^+$  or  $\text{Ca}^{++}$  → depolarization

Excitatory postsynaptic receptor

Activation






## ② Inhibitory Postsynaptic Potentials (IPSP)

- Release of an inhibitory NT
- NT binds to its receptor on the postsynaptic neuron
- Influx of  $\text{Cl}^-$  or efflux of  $\text{K}^+$  → hyperpolarization

Inhibitory postsynaptic receptor









The predominant excitatory neurotransmitter in the brain is  
Glutamate

The predominant inhibitory neurotransmitter in the brain is  
Glycine





# Types of CNS Receptors

- **Excitatory:**

- Ionotropic receptors:

- Nicotinic acetylcholine receptors

They're ligand gated ion channels, 2 molecules of acetylcholine bind to nicotinic receptor which is sodium channels which cause conformational changes in it resulting in opening of sodium channel with influx of sodium ions

- Metabotropic receptors:

- Muscarinic acetylcholine receptors
    - Dopamine (D<sub>1</sub>) receptors

They're G-protein coupled receptor with different types of actions

- **Inhibitory:**

- Ionotropic receptors:

- GABA<sub>A</sub> receptors


They're ligand gated chloride channels, binding of GABA to the receptor causes influx of chloride resulting in hyperpolarization which inhibits postsynaptic neuron

- Metabotropic receptors:

- Opioid receptors
    - GABA<sub>B</sub> receptors

G-protein coupled receptor

Each step in the neurotransmitter cycle is a target for drugs



# Neurotransmitter Cycle

# Sites and Mechanisms of CNS Drug


## Action

Target » voltage gated ion channels »  
inhibition » no depolarization » no action


potential

Inhibit action potential  
presynaptically:

- Local Anesthetics
- General Anesthetics



# Sites and Mechanisms of CNS Drug Action




## Inhibit NT Synthesis:

- Tyrosine hydroxylase (catecholamines)

## Promote NT Synthesis:


- L-dopa

↳ For depression or parkinson





# Sites and Mechanisms of CNS Drug Action




## Interference with storage:

- VMAT is inhibited by *reserpine*
- Consequences? ↴

Preventing packaging » no neurotransmitters to be released

# Sites and Mechanisms of CNS Drug Action




Interfering with action of these enzymes »  
 inhibiting degradation of neurotransmitter »  
 increase in concentration and availability  
 of neurotransmitter at presynaptic cleft

## Metabolism:

- COMT and MAO
- Antiparkinsonian
- Antidepressants

# Sites and Mechanisms of CNS Drug Action




## Release of NT:

- **CNS stimulants**

They increase release of neurotransmitter from presynaptic neuron

# Sites and Mechanisms of CNS Drug Action



## NT action on receptor:


- **Agonist** Drug that binds to a receptor resulting in its activation
- **Antagonist** Drug that binds to a receptor resulting in its inhibition
- **Biased agonist**
- **Allosteric modulators**



Ligand




Either agonist for activation  
or antagonist for inhibition



Allosteric  
modulator


Drugs that bind to a site other than ligand binding site, upon binding they either result with positive allosteric effect resulting in activation of receptor or with negative allosteric effect resulting in inhibition of receptor



~~Negative Allosteric~~  
modulator



# Sites and Mechanisms of CNS Drug Action



## Degradation of NT:

- Acetylcholine esterase

inhibitors → They cross blood brain barrier and work centrally

## Alzheimer's Disease




# Sites and Mechanisms of CNS Drug

## Action

Many neurotransmitters are reuptaken especially dopamine, epinephrine, norepinephrine » they have specialized transporters in the presynaptic neurons

NT reuptake:

• Antidepressants



GABA<sub>A</sub> receptors are example of:

- a) Excitatory ionotropic receptors.
- b) Inhibitory metabotropic receptors.
- c) Voltage-gated channels
- d) Inhibitory ionotropic receptors.
- e) Excitatory metabotropic receptors

Which ion is allowed inside the cell upon GABA<sub>A</sub> receptor stimulation?



You are the leading physician-scientist of the research and development team in a pharmaceutical company. Your team is working on the development of novel therapies to treat Parkinson's disease. Parkinson's disease is characterized by decreased dopaminergic stimulation in the brain. In your research proposal, you include several strategies to improve parkinsonism by targeting different biochemical processes of dopamine signaling. Which of the following mechanisms will NOT be included in your proposal?

- a) Inhibition of the vesicular monoamine transporter 2 (VMAT-2).
- b) Inhibition of catechol-O-methyltransferase (COMT)
- c) Designing more efficacious D<sub>2</sub> receptor agonists.
- d) Designing novel therapies that promote the regeneration of substantia nigra dopaminergic neurons.



- Thank you
- Questions?